<DOC>
	<DOCNO>NCT02175121</DOCNO>
	<brief_summary>This study go assess safety tolerability PF-06291874 adult Type 2 Diabetes Mellitus monotherapy , evaluate significance overall glycemic control subject .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male subject nonchildbearing potential female subject age 18 70 year old . Body Mass Index 18.0 45.4 kg/m2 ; total body weight &gt; 50 kg HbA1c value screen visit meet follow criterion : Currently take acceptable oral antiglycemic drug therapy within 6.5 9.5 % Not currently take oral antiglycemic drug therapy within 7 10.5 % Fasting plasma glucose concentration &lt; 270mg/dL screen runin visit , confirm single repeat , deem necessary . Subjects must willing able perform selftests blood glucose least 4 time per day , maintain diary duration participation study ; therefore , subject must literate . History Type 1 diabetes mellitus secondary form diabetes One selfreported hypoglycemic episode sever intensity within 3 month screen ; 2 selfreported hypoglycemic episode severe intensity within previous 6 month . History myocardial infarction , unstable angina , arterial revascularization , stroke , New York Heart Association Functional Class IIIV heart failure , transient ischemic attach within 6 month screen . History evidence diabetic complication significant end organ damage , Proliferative retinopathy and/or macular edema ; Diabetic neuropathy complicate neuropathic ulcer ; Screening seat systolic blood pressure &gt; 160 mm Hg and/or diastolic blood pressure &gt; 100 mm Hg least 5 minute seat rest . If blood pressure exceed limit , blood pressure may repeat 2 time follow approximately 2 minute rest measurement median 3 value use determine subject eligibility ; Male subject partner currently pregnant ; male subject capable conceive child unwilling unable use highly effective method contraception outline protocol duration study least 28 day last dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>